Exact Sciences Cor EXAS

$HUMA $EXAS sold for $105/share with a smaller potential market cap. Just sayin.

$BLGO The decline is depressing. The opportunity isn’t. 🔥 Clyra’s launch was delayed—not canceled. It doesn’t rely on BLGO to succeed or get financed. The consumer odor product launch is coming soon. Way better terms than they have had with POOPH. And the “Gorilla” partner launch will change everything. 🚀 People mocked my $EXAS conviction all the way to the lows. Then came a 2,000%+ rebound. Different company, but the disconnect between price and potential feels familiar. Could BLGO dip lower? Sure. Timing remains a bit uncertain. But I believe many will regret not adding or averaging down here once execution replaces anticipation. 📈 I’m adding - almost daily. Patience now. Conviction throughout. 💪

$CAI I’m deep 6 figures on this one especially the fact they are proving to be more effective in detecting stage 1 and 2 without symptoms/imagery than any other company. Do your own due diligence and decide for yourself. $GRAL $GH $EXAS $NTRA https://youtu.be/DpkBOG-DAh8?is=lrSaKi4z9w2AR3fS

$HUMA 🔹 Scott Coward: EVP/Chief Legal Officer at Exact Sciences 2015–2022 (the Cologuard ramp), led the Genomic Health integration, and sat on the $EXAS board until Abbott bought it at $105/share in March 2026. Now joins HUMA's Audit Committee. 🔹 Paul Kuznik: 20+ yrs at Abbott Vascular & Diagnostics, then CEO of Bolton Medical (sold to Terumo), then ran Terumo Aortic North America. West Point grad. Joins the Commercial Committee. His Form 3 shows ~222K shares already owned before joining. 🔗 The connections: Chair Kathleen Sebelius also served on the Exact Sciences board alongside Coward. Kuznik is an Abbott veteran, and Abbott is the company that acquired Exact. Coward watched EXAS go from ~$25 to a $4.67 low to a $105 buyout. Kuznik knows how to sell vascular devices to vascular surgeons. That's the playbook HUMA needs for the dialysis launch.

$HUMA Scott was a part of Exact Sciences (EXAS) along with Kathleen Sillibus. $EXAS was $105 a share when it sold to Abbott. I love this addition.

$LUCD i waited 5yrs for $EXAS (lot of us did) and it was the same thing there; thats here... until it wasnt - get off the board and being emotional and stop in from time to time or when its xmas

Precipio, Inc. (NASDAQ: $PRPO ) reported revenue of $7.0 million for the second quarter ended June 30, 2026, the highest quarterly revenue in the company’s history and an increase of 22% from $5.7 million in the second quarter of 2025. The specialty cancer diagnostics company validates its technologies clinically in its own laboratory before commercializing them for the global laboratory community. Precipio, Inc. is a B2i Digital Featured Company. See the company’s in-depth profile at: https://b2idigital.com/precipio-inc-1 Both sides of the business contributed, with pathology services and diagnostic products each growing sequentially: • Revenue surpassed $7 million for the first time in company history, rising from $6.7 million in the first quarter • Product revenue reached $0.9 million, an increase of 21% over the previous high of $750,000 in the fourth quarter of 2025, and pathology revenue reached $6.1 million • Adjusted EBITDA, a non-GAAP measure the company reconciles in the release, was positive at $0.4 million for the quarter • Cash flow from operations was $0.7 million, and cash ended the quarter above $3 million against $1.1 million a year earlier • Management will discuss the quarter on a shareholder call on August 17, 2026 at 5 p.m. ET, followed by a moderated question and answer session The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call. Regarding the cash balance, Ilan Danieli, Chief Executive Officer of Precipio, stated: “We’ve achieved this level of cash without a financing event, demonstrating the strength of our operations. We’re encouraged by the progress we’ve made and believe we are well positioned to continue building on this momentum.” Read the full release: https://www.precipiodx.com/precipio-announces-q2-2026-financial-results/ Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services that deliver higher accuracy, improved laboratory workflow, and better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in its laboratory where it designs, tests, validates, and uses these products clinically, then commercializes them as proprietary products that serve the global laboratory community. More information is available at https://www.precipiodx.com. Discover more emerging growth Featured Companies, Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. $EXAS, $NTRA, $GH, $XBI